Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings per share (EPS) is -0.30.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.08.
EARNINGS PER SHARE (EPS)
-0.30
EARNINGS PER SHARE (EPS) AVG TTM
N/A
EARNINGS PER SHARE (EPS) AVG 3Y
N/A
EARNINGS PER SHARE (EPS) AVG 5Y
N/A
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Starling Oncology, Inc.
Market Cap
$657.89M
Earnings Per Share (EPS)
-0.30
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$656.59M
Earnings Per Share (EPS)
-2.72
TTM Avg
-2.70
3Y Avg
-2.77
5Y Avg
-2.61
Market Cap
$660.29M
Earnings Per Share (EPS)
-1.16
TTM Avg
-1.18
3Y Avg
-1.68
5Y Avg
-2.29
Market Cap
$666.95M
Earnings Per Share (EPS)
-5.51
TTM Avg
-4.06
3Y Avg
-4.55
5Y Avg
-6.70
Market Cap
$673.41M
Earnings Per Share (EPS)
0.04
TTM Avg
0.31
3Y Avg
0.21
5Y Avg
0.05
Market Cap
$638.20M
Earnings Per Share (EPS)
-1.78
TTM Avg
-1.75
3Y Avg
-1.85
5Y Avg
-1.69
Market Cap
$681.02M
Earnings Per Share (EPS)
-2.46
TTM Avg
-3.34
3Y Avg
-3.80
5Y Avg
-4.24
Market Cap
$681.27M
Earnings Per Share (EPS)
-1.91
TTM Avg
-2.52
3Y Avg
-4.99
5Y Avg
-9.27
Market Cap
$634.30M
Earnings Per Share (EPS)
0.93
TTM Avg
-0.44
3Y Avg
-0.74
5Y Avg
-1.38
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Starling Oncology, Inc. (STLN) | $657.89M | -0.30 | N/A | N/A | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $656.59M | -2.72 | -2.70 | -2.77 | -2.61 |
| Annexon, Inc. (ANNX)vs › | $660.29M | -1.16 | -1.18 | -1.68 | -2.29 |
| Helus Pharma Inc. (HELP)vs › | $666.95M | -5.51 | -4.06 | -4.55 | -6.70 |
| MiMedx Group, Inc. (MDXG)vs › | $673.41M | 0.04 | 0.31 | 0.21 | 0.05 |
| Aura Biosciences, Inc. (AURA)vs › | $638.20M | -1.78 | -1.75 | -1.85 | -1.69 |
| Verastem, Inc. (VSTM)vs › | $681.02M | -2.46 | -3.34 | -3.80 | -4.24 |
| Solid Biosciences Inc. (SLDB)vs › | $681.27M | -1.91 | -2.52 | -4.99 | -9.27 |
| Zevra Therapeutics, Inc. (ZVRA)vs › | $634.30M | 0.93 | -0.44 | -0.74 | -1.38 |
| Prime Medicine, Inc. (PRME)vs › | $632.16M | -1.10 | -1.50 | -1.66 | -1.44 |
Trailing EPS (TTM)
$-0.30
Forward EPS (Est.)
$-0.16
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.54 |
